CLINICAL STUDY: CORONARY ARTERY DISEASE
N-acetylcysteine improves coronary and peripheral vascular function
Neil P. Andrews, BMBS, MRCP*,
Abhiram Prasad, MBBS, MRCP* and
Arshed A. Quyyumi, MD, FRCP, FACC*
* Cardiology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
Manuscript received March 21, 2000;
revised manuscript received August 15, 2000,
accepted September 26, 2000.
Reprint requests and correspondence: Dr. Arshed A. Quyyumi, National Institutes of Health, Cardiology Branch, NHLBI, Bldg.10, Rm. 7B15, 10 Center Drive, MSC 1650, Bethesda, Maryland 20892-1650
quyyumia{at}nih.gov
OBJECTIVES
We investigated whether N-acetylcysteine (NAC), a reduced thiol that modulates redox state and forms adducts of nitric oxide (NO), improves endothelium-dependent vasomotion.
BACKGROUND
Coronary atherosclerosis is associated with endothelial dysfunction and reduced NO activity.
METHODS
In 16 patients undergoing cardiac catheterization, seven with and nine without atherosclerosis, we assessed endothelium-dependent vasodilation with acetylcholine (ACH) and endothelium-independent vasodilation with nitroglycerin (NTG) and sodium nitroprusside (SNP) before and after intracoronary NAC. In 14 patients femoral vascular responses to ACH, NTG and SNP were measured before and after NAC.
RESULTS
Intraarterial NAC did not change resting coronary or peripheral vascular tone. N-acetylcysteine potentiated ACH-mediated coronary vasodilation; coronary blood flow was 36 ± 11% higher (p < 0.02), and epicardial diameter changed from –1.2 ± 2% constriction to 4.7 ± 2% dilation after NAC (p = 0.03). Acetylcholine-mediated femoral vasodilation was similarly potentiated by NAC (p = 0.001). Augmentation of the ACH response was similar in patients with or without atherosclerosis. N-acetylcysteine did not affect NTG-mediated vasodilation in either the femoral or coronary circulations and did not alter SNP responses in the femoral circulation. In contrast, coronary vasodilation with SNP was significantly greater after NAC (p < 0.05).
CONCLUSIONS
Thiol supplementation with NAC improves human coronary and peripheral endothelium-dependent vasodilation. Nitroglycerin responses are not enhanced, but SNP-mediated responses are potentiated only in the coronary circulation. These NO-enhancing effects of thiols reflect the importance of the redox state in the control of vascular function and may be of therapeutic benefit in treating acute and chronic manifestations of atherosclerosis.
|
Abbreviations and Acronyms
| | ACH | = acetylcholine | | CV | = coefficient of variation | | NAC | = N-acetylcysteine | | NO | = nitric oxide | | NTG | = nitroglycerin | | SNP | = sodium nitroprusside |
|
This article has been cited by other articles:
|
|
|
|
 
M. Meyer, M. M. LeWinter, S. P. Bell, Z. Chen, D. E. Selby, D. K. Singla, and H. L. Dauerman
N-Acetylcysteine-Enhanced Contrast Provides Cardiorenal Protection
J. Am. Coll. Cardiol. Intv.,
March 1, 2009;
2(3):
215 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Muhammad Anees Sharif, U. Bayraktutan, I. S. Young, and Chee Voon Soong
N-Acetylcysteine Does Not Improve the Endothelial and Smooth Muscle Function in the Human Saphenous Vein
Vascular and Endovascular Surgery,
July 1, 2007;
41(3):
239 - 245.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. P. Forman, E. B. Rimm, and G. C. Curhan
Frequency of Analgesic Use and Risk of Hypertension Among Men
Arch Intern Med,
February 26, 2007;
167(4):
394 - 399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Giustarini, I. Dalle-Donne, S. Lorenzini, A. Milzani, and R. Rossi
Age-related influence on thiol, disulfide, and protein-mixed disulfide levels in human plasma.
J. Gerontol. A Biol. Sci. Med. Sci.,
October 1, 2006;
61(10):
1030 - 1038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Koramaz, Z. Pulathan, S. Usta, S. C. Karahan, A. Alver, E. Yaris, N. I. Kalyoncu, and F. Ozcan
Cardioprotective Effect of Cold-Blood Cardioplegia Enriched with N-Acetylcysteine During Coronary Artery Bypass Grafting
Ann. Thorac. Surg.,
February 1, 2006;
81(2):
613 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Forman, M. J. Stampfer, and G. C. Curhan
Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women
Hypertension,
September 1, 2005;
46(3):
500 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A Vita
Polyphenols and cardiovascular disease: effects on endothelial and platelet function
Am. J. Clinical Nutrition,
January 1, 2005;
81(1):
292S - 297S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Briguori, A. Colombo, F. Airoldi, A. Violante, A. Castelli, P. Balestrieri, P. Paolo Elia, B. Golia, S. Lepore, G. Riviezzo, et al.
N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity
J. Am. Coll. Cardiol.,
August 18, 2004;
44(4):
762 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Briguori, A. Colombo, A. Violante, P. Balestrieri, F. Manganelli, P. Paolo Elia, B. Golia, S. Lepore, G. Riviezzo, P. Scarpato, et al.
Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity
Eur. Heart J.,
February 1, 2004;
25(3):
206 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Robinson
Renal Disease, Homocysteine, and Cardiovascular Complications
Circulation,
January 27, 2004;
109(3):
294 - 295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. M. Fischer, C. S. Cox Jr, S. J. Allen, R. H. Stewart, U. Mehlhorn, and G. A. Laine
The antioxidant N-acetylcysteine preserves myocardial function and diminishes oxidative stress after cardioplegic arrest
J. Thorac. Cardiovasc. Surg.,
November 1, 2003;
126(5):
1483 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Medved, M. J. Brown, A. R. Bjorksten, J. A. Leppik, S. Sostaric, and M. J. McKenna
N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans
J Appl Physiol,
April 1, 2003;
94(4):
1572 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tepel, M. van der Giet, M. Statz, J. Jankowski, and W. Zidek
The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure: A Randomized, Controlled Trial
Circulation,
February 25, 2003;
107(7):
992 - 995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Bonetti, L. O. Lerman, and A. Lerman
Endothelial Dysfunction: A Marker of Atherosclerotic Risk
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2003;
23(2):
168 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Endocr. Rev.,
October 1, 2002;
23(5):
599 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Briguori, F. Manganelli, P. Scarpato, P. P. Elia, B. Golia, G. Riviezzo, S. Lepore, M. Librera, B. Villari, A. Colombo, et al.
Acetylcysteine and contrast agent-associated nephrotoxicity
J. Am. Coll. Cardiol.,
July 17, 2002;
40(2):
298 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sochman
N-acetylcysteine in acute cardiology: 10 years later: What do we know and what would we like to know?!
J. Am. Coll. Cardiol.,
May 1, 2002;
39(9):
1422 - 1428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
